List of Excipients in API vanzacaftor, tezacaftor, and deutivacaftor
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing vanzacaftor, tezacaftor, and deutivacaftor
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | ALYFTREK | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 | CELLULOSE, MICROCRYSTALLINE | 2035-04-14 |
| Vertex Pharmaceuticals Incorporated | ALYFTREK | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 | CROSCARMELLOSE SODIUM | 2035-04-14 |
| Vertex Pharmaceuticals Incorporated | ALYFTREK | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 | FD&C BLUE NO. 1 | 2035-04-14 |
| Vertex Pharmaceuticals Incorporated | ALYFTREK | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 | FERRIC OXIDE RED | 2035-04-14 |
| Vertex Pharmaceuticals Incorporated | ALYFTREK | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 | HYDROXYPROPYL CELLULOSE | 2035-04-14 |
| Vertex Pharmaceuticals Incorporated | ALYFTREK | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 | HYPROMELLOSE | 2035-04-14 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for vanzacaftor, tezacaftor, and deutivacaftor
Excipient focus: CELLULOSE, MICROCRYSTALLINE
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE ACETATE SUCCINATE 06081224
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing HYPROMELLOSE ACETATE SUCCINATE 06081224
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing HYPROMELLOSE ACETATE SUCCINATE 06081224
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
vanzacaftor, tezacaftor, and deutivacaftor drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | vanzacaftor, tezacaftor, and deutivacaftor | 51167-135 |
| >Company | >Ingredient | >NDC |
vanzacaftor, tezacaftor, and deutivacaftor drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links